Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study
|Allergy Autoimmune Diseases Rheumatic Diseases|
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study|
- Incidence of target diseases [ Time Frame: Up to ten years ]Population at risk of target diseases in database will be assessed up to 10 years
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||January 2022|
|Estimated Primary Completion Date:||January 2022 (Final data collection date for primary outcome measure)|
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations.
National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.
Briefly, epidemiology of target disease such as age, sex, incidence and prevalence will be derived from national database. Medical source utilization such as medication and surgery related to target diseases is also available in national database, providing material for cost analysis. These data can be compared with hospital database to ensure validity and reliability.
The investigators study is intended to provide epidemiology of target disease and cost analysis. Interaction between diseases will also be explored.
Target diseases Allergic diseases: Asthma(ICD9 493.x),Steven-Johnson syndrome and other erythroderma (ICD9 695.x)
Autoimmune diseases: Thyroid disease (ICD9 246.x), Addison disease (ICD9 255.x), type 1 diabetes mellitus (250.x1)
Rheumatic diseases: gout (ICD9 274.x), SLE (ICD9 710.0 ), RA (ICD9 714.0), AS and spondylitis (ICD9 720.0&720.x), Psoriasis and psoriatic arthritis (ICD9 696.0), scleroderma (ICD9 710.1), Sjogren's syndrome (ICD9 710.2), dermatomyositis (ICD9 710.3), polymyositis (ICD9 710.4), ANCA vasculitis (WG 446.4, MPA, CSS, PAN ICD9 446.0) or vasculitis 447.6, Behcet's disease(ICD9 136.1), Temporal arteritis(ICD9 446.5), Takayasu arteritis (ICD9 446.7), Henoch-Schonlein purpura (ICD9 287.0)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01611636
|Far Eastern Memorial Hospital||Recruiting|
|New Taipei City, Taiwan, 220|
|Contact: ChienSheng Wu, Master 886931070043 firstname.lastname@example.org|
|Principal Investigator: ChienSheng Wu, Master|
|Principal Investigator:||ChienSheng Wu, Master||Chief, Department of Rheumatic disease|